U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370506) titled 'Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients' on Jan. 18.
Brief Summary: This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Doxorubicin Induced Cardiomyopathy
Intervention:
DRUG: Telmisartan
Telmisartan administered orally once daily as cardio...